NCT00693485 - Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

January 31, 2011

Study Completion Date

August 31, 2011

Conditions

Glaucoma, Open-Angle

Interventions

DRUG

400 ug Brimonidine Implant

400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.

DRUG

200 ug Brimonidine Implant

200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.

DRUG

Sham (no implant)

Sham Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.

Trial Locations (2)

Artesia

Tel Aviv